Floatz logo

RADIUM RA-223

Prostatic Neoplasms, Castration-Resistant

University of California, San FranciscoOtherPhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
81/ 100

Competitive context

229 Active assets in the Prostatic Neoplasms, Castration-Resistant cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
RADIUM RA-223
Bayer
Phase 4BB

View all 50 →

Same molecule, other indications

RADIUM RA-223 is also rated in:

castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
metastatic carcinoma in the boneDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →